• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation?
AF is the most common cardiac arrhythmia worldwide. The estimated prevalence among adults is 2 –4%, and the lifetime risk of developing AF is one in three individuals.1–3 AF is associated with stroke, increasing the risk four- to five-fold while accounting for 20–30% of ischaemic strokes.4,5 In addition, embolic strokes associated with...
Source: Radcliffe Cardiology - June 13, 2023 Category: Cardiology Authors: dbarot525787 Source Type: research

The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights from a Population-Based, Propensity Score-Matched Analysis
Clin Pharmacol Ther. 2021 Oct 31. doi: 10.1002/cpt.2473. Online ahead of print.ABSTRACTThe role of urate-lowering therapy (ULT) for the primary prevention of cardiovascular events has been widely discussed, but its evidence for the secondary prevention of myocardial infarction (MI) is limited. Therefore, we conduct a population-based, propensity score-matched cohort study to investigate the cardiovascular outcomes among post-MI patients with and without ULT. A total of 19,042 newly diagnosed in-hospital MI patients were selected using the Taiwan National Health Insurance Database between 1 January 2005 and 31 December 2016...
Source: Clinical Pharmacology and Therapeutics - October 31, 2021 Category: Drugs & Pharmacology Authors: Chi-Jung Tai Chin-Chung Wu Kun-Tai Lee Tzyy-Guey Tseng Hui-Chun Wang Fang-Rong Chang Yi-Hsin Yang Source Type: research

Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What’s New in the Literature
Atrial fibrillation (AF) is considered the most common sustained cardiac arrhythmia, and it is associated with a significant risk of adverse events, especially ischemic stroke. Oral anticoagulation is the cornerstone for stroke prevention in AF; for many years, only vitamin K antagonists were used for this purpose, with an absolute risk reduction>60%. However, these agents have limitations, such as narrow therapeutic margins and drug–food and drug–drug interactions. More recently, 4 direct-acting oral anticoagulants (DOACs)—non–vitamin K antagonists—have become available for patients with AF: dabigatran, rivaroxa...
Source: Cardiology in Review - April 17, 2021 Category: Cardiology Tags: Review Articles Source Type: research

Atrial fibrillation with percutaneous coronary intervention: Navigating the minefield of antithrombotic therapies
This review aims to provide insights into contemporary therapeutic options for the treatment of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) and compares current international guidelines. AF is a common cardiac arrhythmia and a major risk factor for stroke. The risk of stroke can be reduced with the use of oral anticoagulant (OAC) therapy. However, for patients with AF, PCI necessitates the use of combined antithrombotic therapies (OAC and antiplatelet therapies) to reduce thrombotic coronary complications.
Source: Atherosclerosis - August 29, 2019 Category: Cardiology Authors: Kevin R. Bainey, Jo ão Morais, Uwe Zeymer, Robert C. Welsh Tags: Review article Source Type: research